Fosrenol oral powder sachets launched

Shire has launched a new formulation of lanthanum carbonate (Fosrenol).

The powder sachets may be useful for patients who have difficulty chewing tablets
The powder sachets may be useful for patients who have difficulty chewing tablets

The phosphate binder is now available as 750mg and 1g sachets of oral powder for use in patients who have difficulty with the tablet formulation.

Licensed indications

The powder is licensed for the same indications as the Fosrenol chewable tablet: treatment of hyperphosphataemia in patients with chronic kidney disease (CKD) on haemodialysis or peritoneal dialysis. It can also be used in patients with CKD who are not on dialysis but have a serum phosphate level of 1.78mmol/l or more despite a low phosphate diet.

Adjustable dose regimen

The dose of Fosrenol should be titrated every 2–3 weeks until an acceptable serum phosphate level is achieved. Control is usually achieved at a total daily dose of 1.5–3g.

Administration

The powder should be mixed with a small quantity of soft food and consumed within 15 minutes. Patients should not attempt to dissolve the powder in liquid as it is insoluble.

View Fosrenol Oral Powder drug record
            
Further information: Shire Pharmaceuticals Ltd

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more